Drug profile · INN
tbo-filgrastim
GRANIX
tbo-filgrastim (GRANIX) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — tbo-filgrastim
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
tbo-filgrastim (GRANIX) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tbo-filgrastim?
tbo-filgrastim (GRANIX) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tbo-filgrastim?
GRANIX is a marketed brand name for tbo-filgrastim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tbo-filgrastim?
tbo-filgrastim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.